Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis

American Journal of Physiology - Endocrinology and Metabolism

Volumn 277, Issue 5 40-5, 1999, Pages

  Boushey, Robin P ^a   Yusta, Bernardo ^a   Drucker, Daniel J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Glucagon; Glucagon like peptide 1; Peptide hormone

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE; INDOMETACIN; MYELOPEROXIDASE;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENTERITIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032714919     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1999.277.5.e937     Document Type: Article

References (39)

1. Benjamin, M. A., D. M. McKay, P.-C. Yang, and M. H. Perdue. Glucagon-like peptide-2 enhances epithelial barrier function of both transcellular and paracellular pathways in the mouse (Abstract). Gastroenterology 114: G4620, 1998.
2. Bertrand, V., R. Guimbaud, M. Tulliez, C. Mauprivez, P. Sogni, D. Couturier, J.-P. Giroud, S. Chaussade, and L. Chauvelot-Moachon. Increase in tumor necrosis factor-α production linked to the toxicity of indomethacin for the rat small intestine. Br. J. Pharmacol. 124: 1385-1394, 1998.
3. Bradley, P. P., D. A. Priebat, R. D. Christensen, and G. Rothstein. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78: 206-209, 1982.
4. Chance, W. T., T. Foley-Nelson, I. Thomas, and A. Balasubramaniam. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am. J. Physiol. 273 (Gastrointest. Liver Physiol. 36): G559-G563, 1997.
5. Chomczynski, P., and N. Sacchi. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159, 1987.
6. Drucker, D. J. The glucagon-like peptides. Diabetes 47: 159-169, 1998.
7. Drucker, D. J., and P. L. Brubaker. Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proc. Natl. Acad. Sci. USA 86: 3953-3957, 1989.
8. 2] glucagon-like peptide 2. Am. J. Physiol. 273 (Gastrointest. Liver Physiol. 36): G1252-G1262, 1997.
9. Drucker, D. J., P. Ehrlich, S. L. Asa, and P. L. Brubaker. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA 93: 7911-7916, 1996.
10. Drucker, D. J., Q. Shi, A. Crivici, M. Sumner-Smith, W. Tavares, M. Hill, L. Deforest, S. Cooper, and P. L. Brubaker. Regulation of the biological activity of glucagon-like peptide 2 by dipeptidyl peptidase IV. Nature Biotechnol. 15: 673-677, 1997.
11. 2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am. J. Physiol. 276 (Gastrointest. Liver Physiol. 39): G79-G91, 1999.
12. Edwards, C. M., J. F. Todd, M. Mahmoudi, Z. Wang, R. M. Wang, M. A. Ghatei, and S. R. Bloom. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48: 86-93, 1999.
13. Egger, B., H. V. Carey, F. Procaccino, N.-N. Chai, E. P. Sandgren, J. Lakshmanan, V. S. Buslon, Q. W. French, M. W. Buchler, and V. E. Eysselein. Reduced susceptibility of mice overexpressing transforming growth factor α to dextran sodium sulphate colitis. Gut 43: 64-70, 1998.
14. Egger, B., F. Procaccino, J. Lakshmanan, M. Reinshagen, P. Huffman, A. Patel, W. Reuben, S. Gnanakkan, L. Liu, L. Barajas, and V. E. Eysselein. Mice lacking transforming growth factor a have an increased susceptibility to dextran sulfate-induced colitis. Gastroenterology 113: 825-832, 1997.
15. Ettarh, R. R., and K. E. Carr. Structural and morphometric analysis of murine small intestine after indomethacin administration. Scand. J. Gastroenterol. 28: 795-802, 1993.
16. Housley, R. M., C. F. Morris, W. Boyle, B. Ring, R. Blitz, J. E. Tarpley, S. L. Aukerman, P. L. Devine, R. H. Whitehead, and G. F. Pierce. Keratinocyte growth factor induced proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J. Clin. Invest. 94: 1764-1777, 1994.
17. Kelly, D. A., C. Piasecki, A. Anthony, A. P. Dhillon, R. E. Pounder, and A. J. Wakefield. Focal reduction of villous blood flow in early indomethacin enteropathy: a dynamic vascular study in the rat. Gut 42: 366-373, 1998.
18. Kolligs, F., H.-C. Fehmann, R. Göke, and B. Göke. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19, 1995.
19. Langenbach, R., S. G. Morham, H. F. Tiano, C. D. Loftin, B. I. Ghanayem, P. C. Chulada, J. F. Mahler, C. A. Lee, E. H. Goulding, K. D. Kluckman, H. S. Kim, and O. Smithies. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83: 483-492, 1995.
20. Leung, F. W., J. C. Miller, T. J. Reedy, and P. H. Guth. Exogenous prostaglandin protects against acid-induced deep mucosal injury by stimulating alkaline secretion in rat duodenum. Dig. Dis. Sci. 34: 1686-1691, 1989.
21. Mashimo, H., D.-C. Wu, D. K. Podolsky, and M. C. Fishman. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274: 262-265, 1996.
22. Mojsov, S., G. Heinrich, I. B. Wilson, M. Ravazzola, L. Orci, and J. F. Habener. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 261: 11880-11889, 1986.
23. Munroe, D. G., A. K. Gupta, P. Kooshesh, G. Rizkalla, H. Wang, L. Demchyshyn, Z.-J. Yang, R. K. Kamboj, H. Chen, K. McCallum, M. Sumner-Smith, D. J. Drucker, and A. Crivici. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc. Natl. Acad. Sci. USA 96: 1569-1573, 1999.
24. Nygard, G., A. Anthony, C. Piasecki, M. A. Trevethick, M. Hudson, A. P. Dhillon, R. E. Pounder, and A. J. Wakefield. Acute indomethacin-induced jejunal injury in the rat: early morphological and biochemical changes. Gastroenterology 106: 567-575, 1994.
25. Playford, R. J., T. Marchbank, N. Mandir, A. Higham, K. Meeran, M. A. Ghatei, S. R. Bloom, and R. A. Goodlad. Effects of keratinocyte growth factor (KGF) on gut growth and repair. J. Pathol. 184: 316-322, 1998.
26. Podolsky, D. K. Regulation of intestinal epithelial proliferation: a few answers, many questions. Am. J. Physiol. 264 (Gastrointest. Liver Physiol. 27): G179-G186, 1993.
27. Podolsky, D. K. Healing the epithelium: solving the problem from two sides. J. Gastroenterology 32: 122-126, 1997.
28. Potten, C. S., and H. K. Grant. The relationship between ionizing radiation-induced apoptosis and stem cells in the small and large intestine. Br. J. Cancer 78: 993-1003, 1998.
29. Reuter, B. K., N. M. Davies, and J. L. Wallace. Non-steroidal antiinflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112: 109-117, 1997.
30. Scott, R. B., D. Kirk, W. K. MacNaughton, and J. B. Meddings. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am. J. Physiol 275 (Gastrointest. Liver Physiol. 38): G911-G921, 1998.
31. Scrocchi, L. A., T. J. Brown, N. Maclusky, P. L. Brubaker, A. B. Auerbach, A. L. Joyner, and D. J. Drucker. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nature Med. 2: 1254-1258, 1996.
32. Strober, W., B. R. Ludviksson, and I. J. Fuss. The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease. Ann. Int. Med. 128: 848-856, 1998.
33. Targan, S. R., S. B. Hanauer, S. J. Van Deventer, L. Mayer, D. H. Present, T. Braakman, K. L. Dewoody, T. F. Schaible, and P. J. Rutgeerts. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337: 1029-1035, 1997.
34. Tsai, C.-H., M. Hill, S. L. Asa, P. L. Brubaker, and D. J. Drucker. Intestinal growth-promoting properties of glucagon-like peptide 2 in mice. Am. J. Physiol 273 (Endocrinol. Metab. 36): E77-E84, 1997.
35. Wallace, J. L. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 112: 1000-1016, 1997.
36. Wallace, J. L., K. E. Arfors, and G. W. McKnight. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology 100: 878-883, 1991.
37. Wallace, J. L., C. M. Keenan, and D. N. Granger. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am. J. Physiol. 259 (Gastrointest. Liver Physiol. 22): G462-G467, 1990.
38. Wang, Z., R. M. Wang, A. A. Owji, D. M. Smith, M. A. Ghatei, and S. R. Bloom. Glucagon-like peptide 1 is a physiological incretin in rat. J. Clin. Invest. 95: 417-421, 1995.
39. Yamada, T., E. Deitch, R. D. Specian, M. A. Perry, R. B. Sartor, and M. B. Grisham. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 17: 641-662, 1993.